Clinical trials: Infections, Coronavirus
Covid19
Hamburg Edoxaban for Anticoagulation in COVID-19 Study
Hero-19 aims to evaluate if an intensive anticoagulation strategy using Edoxaban on top of standard of care (SOC) of COVID-19 therapy is superior to SOC (in-hospital moderate anticoagulation strategy = low-dose low-molecular…
- Trial name
- HERO-19 (NCT04542408)
- Testing
- Anticoagulation Agents (Edoxaban and/or high dose LMWH)
- Where
- 10 sites in Germany
- Volunteers
- 140 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
COVID-19
Non-invasive Predictors of ICU Admission and Mortality in Initially Asymptomatic COVID-19 Patients
Coronavirus disease 2019 (COVID-19) can present with pulmonary and non-pulmonary manifestations or it may be asymptomatic. Asymptomatic patients have a major impact on transmission of the disease and prediction of their outcome…
- Trial name
- COVID-HRCT (NCT05298852)
- Testing
- High resolution computed tomography of the chest
- Where
- Egypt
- Volunteers
- 149 people
- Sponsor
- Al-Azhar University
COVID-19
Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients
This is a randomized, double-blind, placebo-controlled, superiority phase IIa trial to assess the safety and efficacy of dupilumab use in hospitalized patients with moderate to severe COVID-19 infection.
- Trial name
- SafeDrop (NCT04920916)
- Testing
- Dupilumab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Covid19, Hemodialysis Complication
Effects of Different Dialysis Strategies on Inflammation in COVID-19 Maintenance Hemodialysis Patients
In the course of Coronavirus Disease-19 (COVID-19) uncontrolled inflammation has been related to disease severity and unfavorable outcomes.
- Conditions
- Covid19, Hemodialysis Complication, Inflammatory Response
- Trial name
- NCT04685447
- Testing
- Expanded Hemodialysis for Covid19 maintenance hemodialysis patients, Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients
- Where
- 2 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Universita degli Studi di Genova
Respiratory Infection, Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired…
- Conditions
- Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- TRICOVID (NCT05531149)
- Testing
- Trimodulin
- Where
- 64 sites in Argentina, Austria and 12 more
- Volunteers
- 107 people
- Sponsor
- Biotest
COVID-19
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, China. The pathogen was soon identified as a novel coronavirus (SARS-CoV-2), which is closely related to severe acute respiratory…
- Trial name
- NCT05195749
- Testing
- 101-PGC-005 ('005) + SOC
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- 101 Therapeutics
Covid19
Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure
Besides protective ventilation with low tidal volumes, prone positioning is a proven intervention to decrease mortality in mechanically ventilated patients with moderate-severe acute respiratory distress syndrome.
- Trial name
- PRO-CARF (NCT04477655)
- Testing
- Awake prone positioning, Standard oxygen therapy
- Where
- 2 sites in Mexico
- Volunteers
- 430 people
- Sponsor
- Hospital Civil de Guadalajara
COVID, Corona Virus Infection
Seroprevalence of SARS-Cov-2 Antibodies in Children
It is unknown what proportion of healthy children have been exposed to SARS-Cov-2 and how many have antibodies. The aim of this study is to follow a cohort of healthy children over six months and measure their antibodies to…
- Conditions
- COVID, Corona Virus Infection, Multisystem Inflammatory Syndrome in Children
- Trial name
- NCT04347408
- Testing
- Covid-19 Antibody testing (IgG and IgM), Blood Storage
- Where
- 5 sites in United Kingdom
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Queen's University, Belfast
COVID-19 Infection
DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1)
This is a pilot study to investigate the safety and feasibility of rhDNase1 and its impact on neutrophil extracellular traps (NETs) in COVID-19 infected patients.
- Trial name
- DISCONNECT-1 (NCT04409925)
- Testing
- rhDNase I
- Where
- 2 sites in Canada
- Volunteers
- 15 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
End Stage Kidney Disease, Kidney Transplantion
The Response of the Immune System of Patients With End Stage Kidney Disease on Dialysis and Kidney Transplant Recipients Vaccinated for COVID-19
Observational study of patients with End Stage Kidney Disease on dialysis and Kidney Transplant Recipients, before and after vaccination for SARS-COV 2, after written consent, with the aim of laboratory efficacy of the vaccine…
- Conditions
- End Stage Kidney Disease, Kidney Transplantion, Covid19, Vaccination
- Trial name
- NCT04932876
- Testing
- SARS - COV 2 VACCINE
- Where
- Greece
- Volunteers
- 100 people
- Sponsor
- University of Ioannina
COVID-19
Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19
Hydroxychloroquine and azithromycin have been proposed as treatment of COVID-19 patients, but few reports have assessed this combination therapy in critically ill COVID-19 patients.
- Trial name
- NCT04452617
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Institut Mutualiste Montsouris
COVID-19, Upper Respiratory Tract Infections
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
TAFFIX is a nasal powder spray that immediately creates a protective acidic barrier on the nasal mucosa against infection by inhaled viruses. The protective barrier lasts 5 hours.
- Trial name
- NCT05252468
- Testing
- TaffiX™
- Where
- Bulgaria
- Volunteers
- 693 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
Acute Kidney Injury, Covid19
CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19
Since the emergence of the new strain of betacoronavirus (SARS-CoV-2) and its important clinical repercussions, it has been described that patients with its associated pneumonia (COVID-19) have high rates of thrombotic events…
- Trial name
- NCT04487990
- Testing
- unfractionated Heparin
- Where
- Brazil
- Volunteers
- 118 people
- Sponsor
- University of Sao Paulo General Hospital
Quality of Life, Intensive Care Unit Syndrome
Patients´ Mental and Physical Health After Covid-19 Treated in ICU in Sweden
Covid-19 is a disease where both clinical experience and thus knowledge about the long-term effects of the disease are currently sparse.
- Trial name
- NCT06042790
- Where
- Sweden
- Volunteers
- 2,500 people
- Sponsor
- Swedish Intensive Care Registry
Intubation Complication
Intubation in Coronavirus Disease 19 With Level 3 PPE
The World Health Organization (WHO) declared COVID-19 as a pandemic in April 2020. COVID-19 first discovered in Wuhan, China in December 2019.
- Trial name
- NCT05108584
- Testing
- PPE Level 3 and Video Laryngoscope, PPE Level 3 and Direct Laryngoscope, PPE Level 2 and Direct Laryngoscope
- Where
- Indonesia
- Volunteers
- 39 people
- Sponsor
- Universitas Indonesia
COVID-19 Pandemic Psychological Impact, Stress
COVID Feel Good-An Easy Self-Help Virtual Reality Protocol to Overcome the Psychological Burden of Coronavirus
This pragmatic trial aims to evaluate whether a weekly self-help virtual reality protocol can help overcome the psychological burden of the COVID-19 pandemic.
- Conditions
- COVID-19 Pandemic Psychological Impact, Stress, Anxiety Disorders, Depression
- Trial name
- NCT06850376
- Testing
- COVID Feel Good VR Self-Help Protocol, Waiting Period
- Where
- Italy
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Istituto Auxologico Italiano
SARS-CoV-2 Respiratory Failure
Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure
Aim. The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide.
- Trial name
- CORMOR (NCT04388514)
- Testing
- Medical Ozone procedure
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Azienda Sanitaria-Universitaria Integrata di Udine
SARS-CoV-2 Infection
Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)
To evaluate the immunogenicity and safety of the third dose SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above, who inoculated the third dose after 6 months since finished two doses schedule of…
- Trial name
- NCT05216484
- Testing
- SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
COVID-19 Infection
Cardiac and Thoracic Imaging in Pediatric Patients With Evidence of Systemic Inflammation COVID19 Linked
To perform comprehensive cardiac and thoracic non invasive imaging assessment by MRI and/or CT scan including cardiac functional evaluation and myocardial tissue characterization of COVID_19 related disease in pediatric patients…
- Trial name
- CARDOVID (NCT04455347)
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Imagine Institute
COVID-19, Vaccine Reaction
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
The goal of this clinical trial is to assess the immunogenicity and safety following a heterologous booster dose of recombinant SARS-CoV-2 vaccine (CHO cell) LYB001 in adults 18-59 years of age completed two- or three-dose…
- Trial name
- NCT05928455
- Testing
- LYB001, CoronaVac
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.